Plasma-mediated immune suppression: A neonatal perspective

Pediatric Allergy and Immunology

Volumn 24, Issue 2, 2013, Pages 102-113

  Belderbos, Mirjam E ^a,b   Levy, Ofer ^c   Meyaard, Linde ^b   Bont, Louis ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Immune regulation; Immune suppression; Neonate; Plasma; Serum; Soluble

Indexed keywords

IMMUNOGLOBULIN; LIPID; PLASMA PROTEIN; PROTEIN; PURINE; SUGAR; TOLL LIKE RECEPTOR;

ADAPTIVE IMMUNITY; ALLERGY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; HUMAN; IMMUNE DEFICIENCY; IMMUNOREGULATION; INFLAMMATION; INNATE IMMUNITY; MEDICAL LITERATURE; MEDICAL RESEARCH; PERINATAL DEVELOPMENT; PLASMA; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

ADAPTIVE IMMUNITY; BLOOD PROTEINS; CARBOHYDRATES; FETAL BLOOD; HUMANS; IMMUNE TOLERANCE; IMMUNITY, INNATE; INFANT, NEWBORN; INFLAMMATION; LIPIDS; PLASMA; PURINES; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84875541127     PISSN: 09056157     EISSN: 13993038     Source Type: Journal    
DOI: 10.1111/pai.12023     Document Type: Review

References (137)

1. Ransohoff RM, Kivisakk P, Kidd G. Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol 2003: 3: 569-81.
2. Wang H, Ma S. The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. Am J Emerg Med 2008: 26: 711-5.
3. Belderbos M, Levy O, Bont L. Neonatal innate immunity in allergy development. Curr Opin Pediatr 2009: 21: 762-9.
4. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev Immunol 2007: 7: 379-90.
5. Lewis DB, Wilson CB. Developmental immunology and role of host defenses in fetal and neonatal susceptibility to infection. In: Remington J, Klein J, eds. Infectious Diseases of the Fetus and Newborn Infant, 5th edn. Philadelphia: Saunders, 2001: 25-138.
6. Carr R. Neutrophil production and function in newborn infants. Br J Haematol 2000: 110: 18-28.
7. Rebuck N, Gibson A, Finn A. Neutrophil adhesion molecules in term and premature infants: normal or enhanced leucocyte integrins but defective L-selectin expression and shedding. Clin Exp Immunol 1995: 101: 183-9.
8. Reddy RK, Xia Y, Hanikyrova M, Ross GD. A mixed population of immature and mature leucocytes in umbilical cord blood results in a reduced expression and function of CR3 (CD11b/CD18). Clin Exp Immunol 1998: 114: 462-7.
9. Levy O, Elsbach P. Bactericidal/Permeability-increasing protein in host defense and its efficacy in the treatment of bacterial sepsis. Curr Infect Dis Rep 2001: 3: 407-12.
10. Kollmann TR, Crabtree J, Rein-Weston A, et al. Neonatal innate TLR-mediated responses are distinct from those of adults. J Immunol 2009: 183: 7150-60.
11. Levy O, Zarember KA, Roy RM, Cywes C, Godowski PJ, Wessels MR. Selective impairment of TLR-mediated innate immunity in human newborns: neonatal blood plasma reduces monocyte TNF-alpha induction by bacterial lipopeptides, lipopolysaccharide, and imiquimod, but preserves the response to R-848. J Immunol 2004: 173: 4627-34.
12. Belderbos ME, van Bleek GM, Levy O, et al. Skewed pattern of Toll-like receptor 4-mediated cytokine production in human neonatal blood: low LPS-induced IL-12p70 and high IL-10 persist throughout the first month of life. Clin Immunol 2009: 133: 228-37.
13. Peoples JD, Cheung S, Nesin M, et al. Neonatal cord blood subsets and cytokine response to bacterial antigens. Am J Perinatol 2009: 26: 647-57.
14. Godfrey WR, Spoden DJ, Ge YG, et al. Cord blood CD4(+) CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. Blood 2005: 105: 750-8.
15. Mayer E, Bannert C, Gruber S, et al. Cord blood derived CD4+ CD25 (high) T cells become functional regulatory T cells upon antigen encounter. PLoS ONE 2012: 7: e29355.
16. Adkins B, Leclerc C, Marshall-Clarke S. Neonatal adaptive immunity comes of age. Nat Rev Immunol 2004: 4: 553-64.
17. Tasker L, Marshall-Clarke S. Immature B cells from neonatal mice show a selective inability to up-regulate MHC class II expression in response to antigen receptor ligation. Int Immunol 1997: 9: 475-84.
18. Corbett NP, Blimkie D, Ho KC, et al. Ontogeny of Toll-like receptor mediated cytokine responses of human blood mononuclear cells. PLoS ONE 2010: 5: e15041.
19. Vanden Eijnden S, Goriely S, De Wit D, Goldman M, Willems F. Preferential production of the IL-12(p40)/IL-23(p19) heterodimer by dendritic cells from human newborns. Eur J Immunol 2006: 36: 21-6.
20. Marchant A, Goetghebuer T, Ota MO, et al. Newborns develop a Th1-type immune response to Mycobacterium bovis bacillus Calmette-Guerin vaccination. J Immunol 1999: 163: 2249-55.
21. Ota MO, Vekemans J, Schlegel-Haueter SE, et al. Influence of Mycobacterium bovis bacillus Calmette-Guerin on antibody and cytokine responses to human neonatal vaccination. J Immunol 2002: 168: 919-25.
22. Belderbos ME, Houben ML, van Bleek GM, et al. Breastfeeding modulates neonatal innate immune responses: a prospective birth cohort study. Pediatr Allergy Immunol 2012: 23: 65-74.
23. Aksoy E, Albarani V, Nguyen M, et al. Interferon regulatory factor 3-dependent responses to lipopolysaccharide are selectively blunted in cord blood cells. Blood 2007: 109: 2887-93.
24. Al-Hertani W, Yan SR, Byers DM, Bortolussi R. Human newborn polymorphonuclear neutrophils exhibit decreased levels of MyD88 and attenuated p38 phosphorylation in response to lipopolysaccharide. Clin Invest Med 2007: 30: E44-53.
25. De Wit D, Olislagers V, Goriely S, et al. Blood plasmacytoid dendritic cell responses to CpG oligodeoxynucleotides are impaired in human newborns. Blood 2004: 103: 1030-2.
26. Goriely S, Van LC, Dadkhah R, et al. A defect in nucleosome remodeling prevents IL-12(p35) gene transcription in neonatal dendritic cells. J Exp Med 2004: 199: 1011-6.
27. Goriely S, Molle C, Nguyen M, et al. Interferon regulatory factor 3 is involved in Toll-like receptor 4 (TLR4)- and TLR3-induced IL-12p35 gene activation. Blood 2006: 107: 1078-84.
28. Belderbos ME, Levy O, Stalpers F, Kimpen JL, Meyaard L, Bont L. Neonatal plasma polarizes TLR4-mediated cytokine responses towards low IL-12p70 and high IL-10 production via distinct factors. PLoS ONE 2012: 7: e33419.
29. Kremer H, Baron-Menguy C, Tesse A, et al. Human serum albumin improves endothelial dysfunction and survival during experimental endotoxemia: concentration-dependent properties. Crit Care Med 2011: 39: 1414-22.
30. van der Poll T, Braxton CC, Coyle SM, et al. Effect of hypertriglyceridemia on endotoxin responsiveness in humans. Infect Immun 1995: 63: 3396-400.
31. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008: 8: 349-61.
32. Hasko G, Kuhel DG, Chen JF, et al. Adenosine inhibits IL-12 and TNF-[alpha] production via adenosine A2a receptor-dependent and independent mechanisms. FASEB J 2000: 14: 2065-74.
33. Hasko G, Kuhel DG, Salzman AL, Szabo C. ATP suppression of interleukin-12 and tumour necrosis factor-alpha release from macrophages. Br J Pharmacol 2000: 129: 909-14.
34. Power Coombs MR, Belderbos ME, Gallington LC, Bont L, Levy O. Adenosine modulates Toll-like receptor function: basic mechanisms and translational opportunities. Expert Rev Anti Infect Ther 2011: 9: 261-9.
35. Yamaguchi Y, Isemura M, Kosakai M, et al. Characterization of fibronectin from fetal human plasma in comparison with adult plasma fibronectin. Biochim Biophys Acta 1984: 790: 53-60.
36. Gringhuis SI, den DJ, Litjens M, van Het HB, van KY, Geijtenbeek TB. C-type lectin DC-SIGN modulates Toll-like receptor signaling via Raf-1 kinase-dependent acetylation of transcription factor NF-kappaB. Immunity 2007: 26: 605-16.
37. Hart PH, Bonder CS, Balogh J, Dickensheets HL, Donnelly RP, Finlay-Jones JJ. Differential responses of human monocytes and macrophages to IL-4 and IL-13. J Leukoc Biol 1999: 66: 575-8.
38. O'Garra A, Murphy KM. From IL-10 to IL-12: how pathogens and their products stimulate APCs to induce T(H)1 development. Nat Immunol 2009: 10: 929-32.
39. Yoshimura A, Muto G. TGF-beta function in immune suppression. Curr Top Microbiol Immunol 2010: 350: 127-47.
40. Granowitz EV, Clark BD, Vannier E, Callahan MV, Dinarello CA. Effect of interleukin-1 (IL-1) blockade on cytokine synthesis: I. IL-1 receptor antagonist inhibits IL-1-induced cytokine synthesis and blocks the binding of IL-1 to its type II receptor on human monocytes. Blood 1992: 79: 2356-63.
41. Martino D, Holt P, Prescott S. A novel role for interleukin-1 receptor signaling in the developmental regulation of immune responses to endotoxin. Pediatr Allergy Immunol 2012: 23: 567-72.
42. Burton J, Kay NE. Does IL-2 receptor expression and secretion in chronic B-cell leukemia have a role in down-regulation of the immune system? Leukemia 1994: 8: 92-6.
43. Protonotariou E, Rizos D, Malamitsi-Puchner A, Moira E, Sarandakou A, Salamalekis E. Cytokine soluble receptors in perinatal and early neonatal life. Mediators Inflamm 2003: 12: 185-8.
44. Sato TA, Widmer MB, Finkelman FD, et al. Recombinant soluble murine IL-4 receptor can inhibit or enhance IgE responses in vivo. J Immunol 1993: 150: 2717-23.
45. Crawley AM, Faucher S, Angel JB. Soluble IL-7R alpha (sCD127) inhibits IL-7 activity and is increased in HIV infection. J Immunol 2010: 184: 4679-87.
46. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996: 334: 1717-25.
47. Narazaki M, Yasukawa K, Saito T, et al. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 1993: 82: 1120-6.
48. Yu RY, Gallagher G. A naturally occurring, soluble antagonist of human IL-23 inhibits the development and in vitro function of human Th17 cells. J Immunol 2010: 185: 7302-8.
49. Lipsky BP, Toy DY, Swart DA, Smithgall MD, Smith DE. Deletion of the ST2 proximal promoter disrupts fibroblast-specific expression but does not reduce the amount of soluble ST2 in circulation. Eur J Immunol 2012: 42: 1863-9.
50. Kessel A, Ammuri H, Peri R, et al. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol 2007: 179: 5571-5.
51. Tawfik DS, Cowan KR, Walsh AM, Hamilton WS, Goldman FD. Exogenous immunoglobulin downregulates T-cell receptor signaling and cytokine production. Pediatr Allergy Immunol 2012: 23: 88-95.
52. Olas K, Butterweck H, Teschner W, Schwarz HP, Reipert B. Immunomodulatory properties of human serum immunoglobulin A: anti-inflammatory and pro-inflammatory activities in human monocytes and peripheral blood mononuclear cells. Clin Exp Immunol 2005: 140: 478-90.
53. Wolf HM, Hauber I, Gulle H, et al. Anti-inflammatory properties of human serum IgA: induction of IL-1 receptor antagonist and Fc alpha R (CD89)-mediated down-regulation of tumour necrosis factor-alpha (TNF-alpha) and IL-6 in human monocytes. Clin Exp Immunol 1996: 105: 537-43.
54. Rajasagi NK, Suryawanshi A, Sehrawat S, et al. Galectin-1 reduces the severity of herpes simplex virus-induced ocular immunopathological lesions. J Immunol 2012: 188: 4631-43.
55. Paclik D, Werner L, Guckelberger O, Wiedenmann B, Sturm A. Galectins distinctively regulate central monocyte and macrophage function. Cell Immunol 2011: 271: 97-103.
56. Tribulatti MV, Figini MG, Carabelli J, Cattaneo V, Campetella O. Redundant and antagonistic functions of galectin-1, -3, and -8 in the elicitation of T cell responses. J Immunol 2012: 188: 2991-9.
57. Chao CC, Molitor TW, Close K, Hu S, Peterson PK. Morphine inhibits the release of tumor necrosis factor in human peripheral blood mononuclear cell cultures. Int J Immunopharmacol 1993: 15: 447-53.
58. Peterson PK, Sharp B, Gekker G, Brummitt C, Keane WF. Opioid-mediated suppression of cultured peripheral blood mononuclear cell respiratory burst activity. J Immunol 1987: 138: 3907-12.
59. Peterson PK, Sharp B, Gekker G, Brummitt C, Keane WF. Opioid-mediated suppression of interferon-gamma production by cultured peripheral blood mononuclear cells. J Clin Invest 1987: 80: 824-31.
60. Shaaban MH, Hung TT, Hoffman DI, Lobo RA, Goebelsmann U. beta-Endorphin and beta-lipotropin concentrations in umbilical cord blood. Am J Obstet Gynecol 1982: 144: 560-8.
61. Da Silva JA. Sex hormones and glucocorticoids: interactions with the immune system. Ann N Y Acad Sci 1999: 876: 102-17.
62. Panayi GS. Anti-inflammatory effect of plasma cortisol. Clin Exp Rheumatol 1987: 5: 297-8.
63. Lang TJ. Estrogen as an immunomodulator. Clin Immunol 2004: 113: 224-30.
64. Bidlingmaier F, Wagner-Barnack M, Butenandt O, Knorr D. Plasma estrogens in childhood and puberty under physiologic and pathologic conditions. Pediatr Res 1973: 7: 901-7.
65. Fijak M, Schneider E, Klug J, et al. Testosterone replacement effectively inhibits the development of experimental autoimmune orchitis in rats: evidence for a direct role of testosterone on regulatory T cell expansion. J Immunol 2011: 186: 5162-72.
66. Schuurs AH, Verheul HA. Effects of gender and sex steroids on the immune response. J Steroid Biochem 1990: 35: 157-72.
67. Penny R, Parlow AF, Frasier SD. Testosterone and estradiol concentrations in paired maternal and cord sera and their correlation with the concentration of chorionic gonadotropin. Pediatrics 1979: 64: 604-8.
68. Schnurr M, Toy T, Shin A, Wagner M, Cebon J, Maraskovsky E. Extracellular nucleotide signaling by P2 receptors inhibits IL-12 and enhances IL-23 expression in human dendritic cells: a novel role for the cAMP pathway. Blood 2005: 105: 1582-9.
69. Wang L, Chen WZ, Wu MP. Apolipoprotein A-I inhibits chemotaxis, adhesion, activation of THP-1 cells and improves the plasma HDL inflammatory index. Cytokine 2010: 49: 194-200.
70. Nagasaka H, Chiba H, Kikuta H, et al. Unique character and metabolism of high density lipoprotein (HDL) in fetus. Atherosclerosis 2002: 161: 215-23.
71. Robbesyn F, Garcia V, Auge N, et al. HDL counterbalance the proinflammatory effect of oxidized LDL by inhibiting intracellular reactive oxygen species rise, proteasome activation, and subsequent NF-kappaB activation in smooth muscle cells. FASEB J 2003: 17: 743-5.
72. Curtiss LK, Edgington TS. Effect of LDL-In, a normal immunoregulatory human serum low density lipoprotein, on the interaction of macrophages with lymphocytes proliferating in response to mitogen and allogeneic stimulation. J Immunol 1977: 118: 1966-70.
73. Curtiss LK, DeHeer DH, Edgington TS. In vivo suppression of the primary immune response by a species of low density serum lipoprotein. J Immunol 1977: 118: 648-52.
74. Loscher CE, Draper E, Leavy O, Kelleher D, Mills KH, Roche HM. Conjugated linoleic acid suppresses NF-kappa B activation and IL-12 production in dendritic cells through ERK-mediated IL-10 induction. J Immunol 2005: 175: 4990-8.
75. Yog R, Barhoumi R, McMurray DN, Chapkin RS. n-3 polyunsaturated fatty acids suppress mitochondrial translocation to the immunologic synapse and modulate calcium signaling in T cells. J Immunol 2010: 184: 5865-73.
76. Gringhuis SI, den DJ, Litjens M, van d V, Geijtenbeek TB. Carbohydrate-specific signaling through the DC-SIGN signalosome tailors immunity to Mycobacterium tuberculosis, HIV-1 and Helicobacter pylori. Nat Immunol 2009: 10: 1081-8.
77. Moro JR, Iwata M, von Andriano UH. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev Immunol 2008: 8: 685-98.
78. Schulz C, Engel U, Kreienberg R, Biesalski HK. Vitamin A and beta-carotene supply of women with gemini or short birth intervals: a pilot study. Eur J Nutr 2007: 46: 12-20.
79. von Bernuth H, Picard C, Jin Z, et al. Pyogenic bacterial infections in humans with MyD88 deficiency. Science 2008: 321: 691-6.
80. Atinmo T, Mbofung C, Osinusi BO. Relationship of zinc and copper concentrations in maternal and cord blood and birth weight. Int J Gynaecol Obstet 1980: 18: 452-4.
81. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006: 6: 772-83.
82. Kotani Y, Yokota I, Kitamura S, Matsuda J, Naito E, Kuroda Y. Plasma adiponectin levels in newborns are higher than those in adults and positively correlated with birth weight. Clin Endocrinol (Oxf) 2004: 61: 418-23.
83. Segerer SE, Muller N, Brandt J, et al. The glycoprotein-hormones activin A and inhibin A interfere with dendritic cell maturation. Reprod Biol Endocrinol 2008: 6: 17.
84. Florio P, Benedetto C, Luisi S, et al. Activin A, inhibin A, inhibin B and parturition: changes of maternal and cord serum levels according to the mode of delivery. Br J Obstet Gynaecol 1999: 106: 1061-5.
85. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010: 11: 785-97.
86. Dierynck I, Bernard A, Roels H, De LM. Potent inhibition of both human interferon-gamma production and biologic activity by the Clara cell protein CC16. Am J Respir Cell Mol Biol 1995: 12: 205-10.
87. Kravitz MS, Pitashny M, Shoenfeld Y. Protective molecules-C-reactive protein (CRP), serum amyloid P (SAP), pentraxin3 (PTX3), mannose-binding lectin (MBL), and apolipoprotein A1 (Apo A1), and their autoantibodies: prevalence and clinical significance in autoimmunity. J Clin Immunol 2005: 25: 582-91.
88. Ren Y, Yang J, Xie R, et al. Exosomal-like vesicles with immune-modulatory features are present in human plasma and can induce CD4+ T-cell apoptosis in vitro. Transfusion 2011: 51: 1002-11.
89. Okunishi K, Dohi M, Nakagome K, et al. A novel role of hepatocyte growth factor as an immune regulator through suppressing dendritic cell function. J Immunol 2005: 175: 4745-53.
90. Horibe N, Okamoto T, Itakura A, et al. Levels of hepatocyte growth factor in maternal serum and amniotic fluid. Am J Obstet Gynecol 1995: 173(Pt 1): 937-42.
91. Akdis CA, Blaser K. Histamine in the immune regulation of allergic inflammation. J Allergy Clin Immunol 2003: 112: 15-22.
92. Gordon LI, Douglas SD, Kay NE, Yamada O, Osserman EF, Jacob HS. Modulation of neutrophil function by lysozyme. Potential negative feedback system of inflammation. J Clin Invest 1979: 64: 226-32.
93. Ogundele MO. A novel anti-inflammatory activity of lysozyme: modulation of serum complement activation. Mediators Inflamm 1998: 7: 363-5.
94. Roozendaal R, Vellenga E, Postma DS, de Monchy JG, Kauffman HF. Nitric oxide selectively decreases interferon-gamma expression by activated human T lymphocytes via a cGMP-independent mechanism. Immunology 1999: 98: 393-9.
95. Urzainqui A, del Martinez HG, Lamana A, et al. Functional role of P-selectin glycoprotein ligand 1/P-selectin interaction in the generation of tolerogenic dendritic cells. J Immunol 2007: 179: 7457-65.
96. Harizi H, Gualde N. Pivotal role of PGE2 and IL-10 in the cross-regulation of dendritic cell-derived inflammatory mediators. Cell Mol Immunol 2006: 3: 271-7.
97. Sewell RD, Jawaharlal K. Antagonism of 2-deoxy-D-glucose-induced hyperphagia by naloxone: possible involvement of endorphins. J Pharm Pharmacol 1980: 32: 148-9.
98. Wittmann M, Kienlin P, Mommert S, Kapp A, Werfel T. Suppression of IL-12 production by soluble CD40 ligand: evidence for involvement of the p44/42 mitogen-activated protein kinase pathway. J Immunol 2002: 168: 3793-800.
99. Cholette JM, Blumberg N, Phipps RP, McDermott MP, Gettings KF, Lerner NB. Developmental changes in soluble CD40 ligand. J Pediatr 2008: 152: 50-4.
100. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996: 2: 1096-103.
101. Ohm JE, Gabrilovich DI, Sempowski GD, et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 2003: 101: 4878-86.
102. Malamitsi-Puchner A, Tziotis J, Tsonou A, Protonotariou E, Sarandakou A, Creatsas G. Changes in serum levels of vascular endothelial growth factor in males and females throughout life. J Soc Gynecol Investig 2000: 7: 309-12.
103. Derive M, Bouazza Y, Sennoun N, et al. Soluble TREM-like transcript-1 regulates leukocyte activation and controls microbial sepsis. J Immunol 2012: 188: 5585-92.
104. Krebs HA. Chemical composition of blood plasma and serum. Annu Rev Biochem 1950: 19: 409-30.
105. Bunn F, Trivedi D, Ashraf S. Colloid solutions for fluid resuscitation. Cochrane Database Syst Rev 2011: 3: CD001319.
106. Gioannini TL, Zhang D, Teghanemt A, Weiss JP. An essential role for albumin in the interaction of endotoxin with lipopolysaccharide-binding protein and sCD14 and resultant cell activation. J Biol Chem 2002: 277: 47818-25.
107. Delaney AP, Dan A, McCaffrey J, Finfer S. The role of albumin as a resuscitation fluid for patients with sepsis: a systematic review and meta-analysis. Crit Care Med 2011: 39: 386-91.
108. Ballow M. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allergy Clin Immunol 2011: 127: 315-23.
109. Eichbaum EB, Harris HW, Kane JP, Rapp JH. Chylomicrons can inhibit endotoxin activity in vitro. J Surg Res 1991: 51: 413-6.
110. Van Lenten BJ, Fogelman AM, Haberland ME, Edwards PA. The role of lipoproteins and receptor-mediated endocytosis in the transport of bacterial lipopolysaccharide. Proc Natl Acad Sci USA 1986: 83: 2704-8.
111. Feingold KR, Funk JL, Moser AH, Shigenaga JK, Rapp JH, Grunfeld C. Role for circulating lipoproteins in protection from endotoxin toxicity. Infect Immun 1995: 63: 2041-6.
112. Harris HW, Rockey DC, Young DM, Welch WJ. Diet-induced protection against lipopolysaccharide includes increased hepatic NO production. J Surg Res 1999: 82: 339-45.
113. Parker TS, Levine DM, Chang JC, Laxer J, Coffin CC, Rubin AL. Reconstituted high-density lipoprotein neutralizes gram-negative bacterial lipopolysaccharides in human whole blood. Infect Immun 1995: 63: 253-8.
114. Banerjee S, Bhaduri JN. Serum protein-bound carbohydrates and lipids in cholera. Proc Soc Exp Biol Med 1959: 101: 340-1.
115. Gallin JI, Kaye D, O'Leary WM. Serum lipids in infection. N Engl J Med 1969: 281: 1081-6.
116. Pajkrt D, Doran JE, Koster F, et al. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med 1996: 184: 1601-8.
117. Grunfeld C, Marshall M, Shigenaga JK, Moser AH, Tobias P, Feingold KR. Lipoproteins inhibit macrophage activation by lipoteichoic acid. J Lipid Res 1999: 40: 245-52.
118. Leong JC, Kane JP, Oleszko O, Levy JA. Antigen-specific nonimmunoglobulin factor that neutralizes xenotropic virus is associated with mouse serum lipoproteins. Proc Natl Acad Sci USA 1977: 74: 276-80.
119. Seganti L, Grassi M, Mastromarino P, Pana A, Superti F, Orsi N. Activity of human serum lipoproteins on the infectivity of rhabdoviruses. Microbiologica 1983: 6: 91-9.
120. Sernatinger J, Hoffman A, Hardman D, Kane JP, Levy JA. Neutralization of mouse xenotropic virus by lipoproteins involves binding to the virions. J Gen Virol 1988: 69(Pt 10): 2657-61.
121. Rifkin MR. Identification of the trypanocidal factor in normal human serum: high density lipoprotein. Proc Natl Acad Sci USA 1978: 75: 3450-4.
122. Shortridge KF, Ho WK, Oya A, Kobayashi M. Studies on the inhibitory activities of human serum lipoproteins for Japanese encephalitis virus. Southeast Asian J Trop Med Public Health 1975: 6: 461-6.
123. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 2000: 192: 1197-204.
124. Schwab JM, Chiang N, Arita M, Serhan CN. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 2007: 447: 869-74.
125. Palmer CD, Mancuso CJ, Weiss JP, Serhan CN, Guinan EC, Levy O. 17(R)-Resolvin D1 differentially regulates TLR4-mediated responses of primary human macrophages to purified LPS and live E. coli. J Leukoc Biol 2011: 90: 459-70.
126. Levy BD, Kohli P, Gotlinger K, et al. Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J Immunol 2007: 178: 496-502.
127. Levy O, Coughlin M, Cronstein BN, Roy RM, Desai A, Wessels MR. The adenosine system selectively inhibits TLR-mediated TNF-alpha production in the human newborn. J Immunol 2006: 177: 1956-66.
128. Ramakers BP, Riksen NP, van den BP, et al. Circulating adenosine increases during human experimental endotoxemia but blockade of its receptor does not influence the immune response and subsequent organ injury. Crit Care 2011: 15: R3.
129. Geijtenbeek TB, Gringhuis SI. Signalling through C-type lectin receptors: shaping immune responses. Nat Rev Immunol 2009: 9: 465-79.
130. Fujita T, Matsushita M, Endo Y. The lectin-complement pathway-its role in innate immunity and evolution. Immunol Rev 2004: 198: 185-202.
131. Nakao M, Yano T. Structural and functional identification of complement components of the bony fish, carp (Cyprinus carpio). Immunol Rev 1998: 166: 27-38.
132. Verga Falzacappa MV, Segat L, Puppini B, Amoroso A, Crovella S. Evolution of the mannose-binding lectin gene in primates. Genes Immun 2004: 5: 653-61.
133. U.S. Food and drug administration. 13 April 2011.
134. Provan D, Nokes T, Agrawal S, Winer J, Wood P. Clinical Guidelines for Immunoglobulin Use 2008. 30 May 2011.
135. Palmer CD, Guinan EC, Levy O. Deficient expression of bactericidal/permeability-increasing protein in immunocompromised hosts: translational potential of replacement therapy. Biochem Soc Trans 2011: 39: 994-9.
136. Perlmutter SJ, Leitman SF, Garvey MA, et al. Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Lancet 1999: 354: 1153-8.
137. Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2008: 1: CD002277.